Cited by 379Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Open access

Boonen, Steven, Reginster, Jean-Yves, Kaufman, Jean-Marc, Lippuner, Kurt, Zanchetta, Jose, Langdahl, Bente, Rizzoli, Rene, Lipschitz, Stanley, Dimai, Hans Peter, Witvrouw, Richard, Eriksen, Erik, Brixen, Kim, Russo, Luis, Claessens, Frank, Papanastasiou, Philemon, Antunez, Oscar, Su, Guoqin, Bucci-Rechtweg, Christina, Hruska, Josef, Incera, Elodie, Vanderschueren, Dirk, Orwoll, Eric·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1204061

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. RESULTS: The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). CONCLUSIONS: Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1204061

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,822
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citation
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citation
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Nguyen, T. V., Schneider, D. L., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 201–300 of 379

Male osteoporosis
Giusti, A., & Bianchi, G. (2014) · Reumatismo · doi:10.4081/reumatismo.2014.786 · Cited by 8
Association between total and animal proteins with risk of fracture: A systematic review and dose–response meta-analysis of cohort studies
Zeraattalab-Motlagh, S., Mortazavi, A., Ghoreishy, S. M., & Mohammadi, H. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06948-8 · Cited by 7
Rationale for osteoporosis screening in men
Narla, R. R., & Adler, R. A. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07337-5 · Cited by 7
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
Villegas‐Vázquez, E. Y., Marín-Carrasco, F. P., Reyes‐Hernández, O. D., Báez-González, A. S., Bustamante-Montes, L. P., Padilla‐Benavides, T., Granados, L. I. Q., & Figueroa‐González, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514120 · Cited by 8
Osteoporosis in Men
Adler, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_24 · Cited by 7
Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
Sun, J., Rahmati, M., Xie, W., Yang, G., Ji, B., Yon, D. K., Lee, S. W., Gyasi, R. M., Sánchez, G. F. L., Soysal, P., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33871 · Cited by 8
Factores que predicen el desarrollo de metástasis óseas por cáncer de próstata: recomendaciones de seguimiento y opciones terapéuticas
Rodríguez-Antolín, A., Gómez-Veiga, F., Álvarez-Osorio, J. K., Carballido, J., Palou, J., Solsona-Narbón, E., Sánchez Sánchez, E., & Unda, M. (2013) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2013.09.002 · Cited by 7
Zoledronic Acid for prevention of bone and muscle loss after BAriatric Surgery (ZABAS)-a study protocol for a randomized controlled trial
Gam, S., Gram, B., Juhl, C. B., Hermann, A. P., & Hansen, S. G. (2022) · Trials · doi:10.1186/s13063-022-06766-z · Cited by 6
Osteoporosis in men—East and West: Can the twain meet? A perspective from Asia
Sng, G. G. R., Reginster, J., Alokail, M. S., & Chandran, M. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2024.11.001 · Cited by 9
Documento de consenso de osteoporosis del varón
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.12.005 · Cited by 6
Features of osteoporosis in male patients with bronchiectasis, a cross-sectional study
Xu, G., Zhao, J., Liu, F., Cai, D., Feng, C., Wang, L., Zeng, Y., Liu, Y., Wu, S., Chen, Y., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-887 · Cited by 6
Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients
Lin, T., Yang, S.-C., Tsai, T., Lai, P., Fu, T., Niu, C., Chen, L.-H., & Chen, W. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1151775 · Cited by 6
Femoral head trabecular micro-architecture in patients with osteoporotic hip fractures: Impact of bisphosphonate treatment
Yoon, B., Kim, J.-G., Lee, Y., Ha, Y., Koo, K., & Kim, J. H. (2017) · Bone · doi:10.1016/j.bone.2017.08.020 · Cited by 6
Gonadal Hormones and Bone
Yoshida, T., Wang, J., & Stern, P. H. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_327 · Cited by 6
Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
Zhang, J., Yan, B., Chen, Z., Zheng, Z., & Yang, C. (2020) · Asian Spine Journal · doi:10.31616/asj.2020.0282 · Cited by 6
Osteoporosis in Men
ORWOLL, E. S., Vanderschueren, D., & Boonen, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00032-7 · Cited by 6
Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era
VIOLI, A., FORTUNATO, V., D’Amuri, A., Zuliani, G., Basili, S., Passaro, A., Corica, B., & Raparelli, V. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04893-4 · Cited by 6
Choosing the appropriate treatment strategy for osteoporosis in men
Potoupnis, M. E., Kenanidis, E. I., Anagnostis, P. G., & Tsiridis, E. E. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1743266 · Cited by 6
Protocol for preliminary, multicenteric validation of “PoCOsteo device”: A point of care tool for proteomic and genomic study of osteoporosis
Razi, F., Ostovar, A., Fahimfar, N., Amoli, M. M., Fana, S. E., Dimai, H. P., Obermayer-Pietsch, B. M., Luegger, B., Rivadeneira, F., Nabipour, I., et al. (2024) · Biology Methods and Protocols · doi:10.1093/biomethods/bpae006 · Cited by 5
Synthesis and Promotion of the Osteoblast Proliferation Effect of Morroniside Derivatives
Han, H., Li, Z., Qu, N., Chen, S., & Dong, P. (2018) · Molecules · doi:10.3390/molecules23061412 · Cited by 5
Understanding Osteoporosis: Pathophysiology, Risk Factors, Diagnosis, and Management
Ismail, M. (2024) · Advances in Aging Research · doi:10.4236/aar.2024.133003 · Cited by 5
Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options
Rodríguez-Antolín, A., Gómez-Veiga, F., Álvarez-Osorio, J. K., Carballido, J., Palou, J., Solsona-Narbón, E., Sánchez Sánchez, E., & Unda, M. (2014) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2014.01.001 · Cited by 5
Osteoporosis: Prevention and Treatment
Zaheer, S., & LeBoff, M. S. (2016) · Cited by 5
Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance
Takada, J., Sato, S., Arai, K., Kito, Y., Oshita, Y., & Saito, K. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01410-5 · Cited by 5
The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis
Kondo, S., Kakihata, H., Nishida, Y., Furuno, Y., Kobayashi, Y., Tabata, H., & Nomura, M. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0915-2 · Cited by 5
Correlation of hip fracture with other fracture types: Toward a rational composite hip fracture endpoint
Colon-Emeric, C. S., Pieper, C. F., Grubber, J. M., Scoyoc, L. V., Schnell, M. L., Houtven, C. H. V., Pearson, M., LaFleur, J., Lyles, K. W., & Adler, R. A. (2015) · Bone · doi:10.1016/j.bone.2015.07.003 · Cited by 5
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: Is This All We Need to Know?
Bischoff-Ferrari, H. A., & Meyer, O. (2014) · Annals of Internal Medicine · doi:10.7326/m14-1942 · Cited by 5
Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture
Wu, T., Tsou, Y., Wu, W., Lee, R., Wang, J., & Yeh, K. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2378 · Cited by 4
Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar
Alam, F., Alsaed, O. S., Abdulla, N., Abdulmomen, I., Lutf, A. Q. A., & Emadi, S. A. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01389-0 · Cited by 10
Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate
Al-Bogami, M. M., Alkhorayef, M. A., Byström, J., Akanle, O. A., Adhoubi, N. K. A., Jawad, A. S. M., & Mageed, R. A. (2015) · Saudi Medical Journal · doi:10.15537/smj.2015.11.12731 · Cited by 4
Osteoporosis
Chapurlat, R. D., & Genant, H. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00069-x · Cited by 4
Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center
Bareli, N., Gat, R., Makarov, V., Siris, E. S., Fraenkel, M., & Yoel, U. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00944-3 · Cited by 4
Zoledronic acid for osteoporosis and associated low-energy fractures
Rodionova, S. S., Kolondaev, A. F., Torgashin, A. N., & Анатольевна, С. И. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-21-163-173 · Cited by 4
A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”
Leder, B. Z., Clarke, B. L., Shane, E. J., Khosla, S., & Kiel, D. P. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3823 · Cited by 4
Association Between Bisphosphonates Therapy and Incident Myocardial Infarction
Huang, B., Huang, F., Gui, Y.-Y., Peng, Y., Liu, W., Huang, K., Zhang, C., Zuo, Z., Liao, Y., Xia, T., et al. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000298 · Cited by 4
Cancer Treatment-Induced Bone Loss (CTIBL)
Abreu, C., Dionísio, M. R., da Silva, J. C. F., & Costa, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66136-6 · Cited by 4
Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease
Sun, X., Leder, B. Z., Ly, T. V., Franco‐Garcia, E., Bolster, M. B., & Fan, W. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf195 · Cited by 3
Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis
Zhou, B., Zhang, Y., Yu, W., Sun, L., Wang, Y., Jiang, Y., Wang, O., Xing, X., Xia, W., Zhang, J., et al. (2026) · Age and Ageing · doi:10.1093/ageing/afag121 · Cited by 3
Osteoporosis in men of the endocrinology outpatient clinic in Manizales city, Colombia
Lozada, A. S., & Maya, D. A. D. L. P. (2019) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.10.003 · Cited by 3
Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis
Chen, L., Ji, B., & Xia, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1558560 · Cited by 3
Calcium and bone metabolism
Wass, J. A. H., Owen, K. R., & Turner, H. E. (2014) · doi:10.1093/med/9780199644438.003.0006 · Cited by 3
Consensus document on osteoporosis in males
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.12.003 · Cited by 3
EFFECTS OF ZOLEDRONIC ACID ON OSTEOBLAST PROLIFERATION AND IGF-1 EXPRESSIONS IN RATS IN VITRO
Huang, J. (2019) · FARMACIA · doi:10.31925/farmacia.2019.1.21 · Cited by 3
Efficacy of zoledronic acid in older prostate cancer patients undergoing androgen deprivation therapy
Kojima, I., Naito, Y., Yamamoto, A., Terashima, Y., Sho, N., Nagayama, J., Okada, Y., & Nagai, T. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.11.001 · Cited by 3
Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis
Mochizuki, T., Yano, K., Ikari, K., & Okazaki, K. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6607-20 · Cited by 3
Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study
Mochizuki, T., Yano, K., Ikari, K., & Okazaki, K. (2022) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2022.05.001 · Cited by 3
Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study
Bliuc, D., Tran, T. S., Chen, W., Alarkawi, D., Alajlouni, D. A., Blyth, F., MARCH, L. M., & Blank, R. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac669 · Cited by 3
Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis
Dong, A., Fei, X., Huang, Y., & Huang, Y. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01407-0 · Cited by 3
Gaps in evidence on treatment of male osteoporosis: a Research Agenda
Rose, A. J., Greenspan, S. L., & Jasuja, G. K. (2023) · The Aging Male · doi:10.1080/13685538.2023.2223699 · Cited by 3
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
Crandall, C. J., Newberry, S. J., Diamant, A. L., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. (2020) · Annals of Internal Medicine · Cited by 3
Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis
Konsta, M. A. P., Bournia, V.-K., Dania, V., & Iliopoulos, A. (2014) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000114 · Cited by 3
Impact of regulatory assessment on clinical studies in Brazil
Russo, L. A. T., Eliaschewitz, F. G., Harada, V., Trefiglio, R. P., Picciotti, R., Machado, P. G. P., & Kesselring, G. L. F. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.05.447 · Cited by 3
Protosappanin a inhibits osteoclastogenesis via reducing oxidative stress in RAW264.7 cells.
Huang, Q., Meng, R.-Y., Yang, Y., Li, M., Wang, F., Shen, W.-W., Deng, X., Zhou, S., Xue, Y., & Gao, Q. (2017) · PubMed Central · Cited by 3
Adverse Cardiac Effects of Bisphosphonates
Keller, D. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.012 · Cited by 3
Morbidity associated with osteoporosis significant in older men
Grewal, S., & Jawad, A. S. M. (2022) · Trends in Urology & Men s Health · doi:10.1002/tre.868 · Cited by 2
Evaluación, diagnóstico diferencial y tratamiento de la osteoporosis vertebral: cómo evitar la aparición de nuevas fracturas
Nikitsina, M., Quiroga-Colina, P., & Castañeda, S. (2024) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2024.06.011 · Cited by 2
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis
Gal, Z. T., Wetzel, E. A., Nahed, B. V., Saylor, P. J., Hirsch, J. A., Marciscano, A. E. E., Raje, N. S., Tobert, D. G., Yee, A. J., & Shankar, G. M. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.10.018 · Cited by 2
Nf2 orchestrates β-arrestin2-biased PTH1R signaling to couple bone mass with skeletal integrity
Liao, J., He, Y., Zhang, C., Qian, Q., Huang, Y., Zhang, Q., Shen, P., Zhou, C., Wu, M., & Chen, G. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524671123 · Cited by 2
Surrogate markers in assessment of bisphosphonate effectiveness in osteoporosis treatment (bone mineral density, bone turnover markers)
Belaya, Z. E., & Rozhinskaya, L. Y. (2024) · Osteoporosis and Bone Diseases · doi:10.14341/osteo13166 · Cited by 2
Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients
Zhang, Q., Gao, W., Xu, X., Cui, R., & Su, B. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07448-7 · Cited by 2
Fragility of Evidence for the Efficacy of Anti-Fracture Medications
Tran, N., Tran, T. S., & Nguyen, T. V. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf332 · Cited by 2
Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers
Harper, S. N., Remer, E. M., & Almassi, N. (2025) · Current Urology Reports · doi:10.1007/s11934-025-01278-0 · Cited by 2
Aspects of practical application of ‘STOPP/START’ criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi‑speciality hospital
Владимировна, Б. С., Ostroumova, O. D., Кочетков, А. И., Ebzeeva, E. Y., Romanovsky, R. R., Shatalova, N. A., Сергеевна, Ч. М., & Sychev, D. A. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-1-57-65 · Cited by 3
Chapter 32 – Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization
ORWOLL, E. S., Vanderschueren, D., & Boonen, S. (2013) · Cited by 2
Men’s health and osteoporosis: modern treatment and prevention options
Biryukova, E. V., & Викторович, Ш. М. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-21-1-120-129 · Cited by 2
Yaşlanma ve Egzersiz
Torlak, M. S. (2018) · Spor Bilimleri Araştırmaları Dergisi · doi:10.25307/jssr.423106 · Cited by 2
Management of Male Osteoporosis
Geusens, P., & van den Bergh, J. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-26757-9_7 · Cited by 2
Osteoporosis in men: what is similar and what is different?
Laurent, M. R., Gielen, E., ORWOLL, E. S., & Vanderschueren, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00025-3 · Cited by 2
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch37 · Cited by 2
Zoledronic Acid for prevention of bone and muscle loss after BAriatric Surgery (ZABAS) – A study protocol for a randomized controlled trialPreprint
Gam, S., Gram, B., Juhl, C. B., Hermann, A. P., & Hansen, S. G. (2022) · Research Square · doi:10.21203/rs.3.rs-1188383/v1 · Cited by 2
Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study
Du, Y., Yu, W., Gou, H., Lei, Y., Zhang, T., Tang, W., Chen, M., Li, H., & Cheng, Q. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07781-8 · Cited by 1
Proceedings of the 2025 Santa Fe Bone Symposium: Current concepts in the care of patients with osteoporosis, parathyroid disorders, and rare bone diseases
Lewiecki, E. M., Adler, R. A., Anderson, P. A., Bilezikian, J. P., Dempster, D. W., Fazeli, P. K., McClung, M. R., Rush, E. T., Swanson, C. M., & Tanner, S. B. (2025) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2025.101628 · Cited by 1
Inequities Across the Spectrum of Osteoporosis Care and Post-Fracture Management in Men
Almeida, R. J. R. D., Grover, A. K., Agarwal, S., & Dhaliwal, R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00939-w · Cited by 1
Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis
Xiao, M., Liu, F., & Duan, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1716931 · Cited by 1
The influence of anti-osteoporotic drugs on fracture risk, bone mineral density, and side effect in senile osteoporosis treatment: a network meta-analysis of randomized controlled trials
Zhou, Z., Yang, Q., Liu, L., Guo, W., Xu, F., Liu, Y., Li, X., Wu, Y., Zhou, N., Yao, H., et al. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45032 · Cited by 1
Observational studies—just telling us what we want to hear or telling us where we need to look?
Reid, I. R., & Bolland, M. J. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1928 · Cited by 1
Complications of ADT for Prostate Cancer: Osteoporosis and the Risk of Fracture
Uemura, H. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_16 · Cited by 1
Osteoporosis en hombres de la consulta de endocrinología en la ciudad de Manizales, Colombia
Lozada, A. S., & Maya, D. A. D. L. P. (2019) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2019.10.002 · Cited by 1
Osteoporosis in Men
Costa, A. G., Cusano, N. E., Silva, B. C. C., & Bilezikian, J. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_25 · Cited by 1
Efficacy of Zoledronic Acid in Patients with Systemic Osteoporosis and Problem of «Non Respondents» to the Treatment
Rodionova, S. S., & Buklemishev, Y. V. (2015) · N N Priorov Journal of Traumatology and Orthopedics · doi:10.17816/vto201522439-43 · Cited by 1
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Ruggiero, C., Caffarelli, C., Calsolaro, V., Tafaro, L., Riuzzi, F., Bubba, V., Napoli, N., Ferracci, M., Mecocci, P., Giusti, A., et al. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01163-4 · Cited by 1
A Review of the 2008 Singapore Ministry of Health Clinical Practice Guidelines on Osteoporosis and an Update
Tan, M. Z., Chionh, S. B., & Chandran, M. (2012) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.027.02.05 · Cited by 1
Testosterone and Male Osteoporosis
Shin, D.-E., Ahn, T., Kim, J.-W., Oh, C.-H., & Choi, S. (2018) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-018-9245-0 · Cited by 2
Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis
Radwan, I. A., Korany, N. S., & Ezzat, B. A. (2018) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2018.75030 · Cited by 1
Management of Male Osteoporosis: an Update
Almohaya, M. S., Alobedollah, A., & Kendler, D. L. (2018) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-018-0107-1 · Cited by 1
Back pain and spinal osteoporosis in clinical practice
Пизова, Н. В., & Pizov, A. V. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-18-119-126 · Cited by 1
Osteoporosis in Men
Adler, R. A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_20 · Cited by 1
Zoledronic acid prevents vertebral fractures in men with osteoporosis
(2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.28 · Cited by 1
Osteoporoza pri moških – pomen hipogonadizma
Antonič, K. G., & Kocjan, T. (2023) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3435
Pharmacological Therapy
Fornari, R., Greco, E. A., Lenzi, A., & Migliaccio, S. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-96376-1_17 · Cited by 1
Osteoporosis in Men
ORWOLL, E. S., & Adler, R. A. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch56 · Cited by 2
Bisphosphonates Trigger Anti-Ageing Effects Across Multiple Cell Types and Protect Against SenescencePreprint
Lu, J., Rao, S. R., Knowles, H. J., Zhan, H., Gámez, B., Platt, E., Frost, L. R., Allen, T.-J., Marshall, G. B., Huber, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.25.645228 · Cited by 1
Rethinking osteoporosis
Smith, A., Shaw, B., Laliberte, D., Langston, J., & Bushardt, R. L. (2013) · JAAPA · doi:10.1097/01.jaa.0000432496.47021.62
Diferencias entre las características basales de los pacientes en los ensayos clínicos, según el tamaño de la muestra. Un estudio meta-epidemiológico
Isaza, D., Gómez, M. Z., & Gómez, J. R. M. (2013) · Revista Digital Palabra (Universidad Pontificia Bolivariana)
Bisphosphonates for preventing and treating osteoporosis in men
Sim, I., Ebeling, P. R., & Buchbinder, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011074
Retracted
Preventing and treating osteoporosis in men
O’Connell, M. B., & Vondracek, S. F. (2013) · Pharmacy Today · doi:10.1016/s1042-0991(15)31276-7
Impact of Clinical Study Regulatory Approval Delays in Brazil
Kesselring, G. L. F., Harada, V., Eliaschewitz, F. G., Picciotti, R., Machado, P. G. P., & Russo, L. A. T. (2014) · doi:10.14524/cr-14-0027
A Interventional Study in a Real Life Setting to Assess the Clinical Efficacy and Effect on Fracture in the 1 Year after Injection of Zoledronic Acid in Osteoporotic Patients with Long Bone or Spine, Pelvic Fractures
Lee, J., Kim, J., Kang, B., Kim, J., Park, K.-C., & Park, Y. (2016) · The Journal of the Korean Orthopaedic Association · doi:10.4055/jkoa.2016.51.4.320
New Approaches to Osteoporosis Therapeutics
Costa, A. G., Cusano, N. E., Silva, B. C. C., & Bilezikian, J. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00086-8
A interventional study in a real life setting to assess the clinical efficacy and effect to fracture in the 1 year after the injection of zoledronic acid in osteoporotic patients with long bone or spine, pelvic fractures
Lee, J., Kim, J., Park, K.-C., & Park, Y. (2016) · Bone Abstracts · doi:10.1530/boneabs.5.p383

Authors: Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., Incera, E., Vanderschueren, D., & Orwoll, E.
Affiliations: KU Leuven (BE)
University of Liège (BE)
Ghent University (BE)
University of Bern (CH)
Aarhus University Hospital (DK)
Medical University of Graz (AT)
Ziekenhuis Oost-Limburg (BE)
University of Oslo (NO)
University of Southern Denmark (DK)
Novartis (Switzerland) (CH)
Oregon Health & Science University (US)
ORCID: Reginster, Jean-Yves
Kaufman, Jean-Marc
Lippuner, Kurt
Langdahl, Bente
Dimai, Hans Peter
Eriksen, Erik
Claessens, Frank
Bucci-Rechtweg, Christina
Incera, Elodie
Vanderschueren, Dirk
Orwoll, Eric
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11
Volume: 367
Issue: 18
Pages: 1714-1723
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1204061
OpenAlex: W2123816368
Cited by: 359
References: 30
Citations by year: 2026: 17 · 2025: 24 · 2024: 23 · 2023: 21 · 2022: 25 · 2021: 25 · 2020: 26 · 2019: 24 · 2018: 30 · 2017: 21 · 2016: 28 · 2015: 23 · 2014: 29 · 2013: 36 · 2012: 5
FWCI: 32.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
BORIS (University Library Bern) (submittedVersion, other-oa)
IRIS (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Open Access CRIS of the University of Bern
Funders: U.S. Department of Justice
Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Teva Pharmaceutical Industries
Danone
University of Bern
Union Chimique Belge
Daiichi-Sankyo
Novo Nordisk
Servier
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, male osteoporosis, vertebral fractures, fracture risk reduction, bisphosphonates, androgen deficiency, bone mineral density, bone turnover markers, height loss
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Analysis of Variance, Diphosphonates, Double-Blind Method, Humans, Hypogonadism, Imidazoles, Male, Middle Aged, Osteoporosis, Risk, Testosterone, Bone Density, Logistic Models, Spinal Fractures, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks